NCT06104345View on ClinicalTrials.gov

Immune Response Elicited by Concomitant Administration of Oral Typhoid Fever (Vivotif®) and Cholera (Dukoral®) Vaccines

PHASE4CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

October 25, 2023

Primary Completion Date

June 26, 2024

Study Completion Date

June 26, 2024

Conditions
Vaccine-Preventable DiseasesTyphoid FeverCholera
Interventions
BIOLOGICAL

Oral typhoid fever vaccine

Oral typhoid fever vaccine (Vivotif®) on Days 0, 2 and 4.

BIOLOGICAL

Oral cholera vaccine

Oral cholera vaccine (Dukoral®) on Days 0 and 7.

Trial Locations (1)

00290

Meilahti Vaccine Research Center, Helsinki University Hospital, Helsinki

All Listed Sponsors
collaborator

University of Helsinki

OTHER

lead

Helsinki University Central Hospital

OTHER

NCT06104345 - Immune Response Elicited by Concomitant Administration of Oral Typhoid Fever (Vivotif®) and Cholera (Dukoral®) Vaccines | Biotech Hunter | Biotech Hunter